Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Income from Continuing Operations (2016 - 2025)

Arrowhead Pharmaceuticals' Income from Continuing Operations history spans 16 years, with the latest figure at 28242000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 116.12% year-over-year to 28242000.0; the TTM value through Dec 2025 reached 233574000.0, up 135.96%, while the annual FY2025 figure was 30114000.0, 104.94% up from the prior year.
  • Income from Continuing Operations reached 28242000.0 in Q4 2025 per ARWR's latest filing, up from 16121000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 367863000.0 in Q1 2025 to a low of 178652000.0 in Q2 2025.
  • Average Income from Continuing Operations over 5 years is 52860250.0, with a median of 67710000.0 recorded in 2021.
  • Peak YoY movement for Income from Continuing Operations: tumbled 366.37% in 2024, then surged 389.67% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 62872000.0 in 2021, then skyrocketed by 33.53% to 41794000.0 in 2022, then crashed by 223.91% to 135376000.0 in 2023, then dropped by 29.43% to 175218000.0 in 2024, then soared by 116.12% to 28242000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Income from Continuing Operations are 28242000.0 (Q4 2025), 16121000.0 (Q3 2025), and 178652000.0 (Q2 2025).